Serina Therapeutics Inc (SER) Noticias

Form 8-K - Current report

Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Meet with Serina’s CEO Steven A. LedgerParkinson's disease is a progressive neurological disorder that...

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit

HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a...

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

HUNTSVILLE, AL, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form DEFC14A - Definitive proxy statement, contested solicitations